{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:31:21Z","timestamp":1777937481777,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSP2024R77"],"award-info":[{"award-number":["RSP2024R77"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jsps.2024.102203","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T22:13:57Z","timestamp":1730758437000},"page":"102203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3141-0606","authenticated-orcid":false,"given":"Abdulaali R.","family":"Almutairi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walaa A.","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghaida K.","family":"Alhathlol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah","family":"Alsheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz","family":"Alakeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed S.","family":"Al Yami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Fouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meshal S.","family":"Alhamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awatif","family":"Hafiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussam","family":"Kutbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Bagalagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashael","family":"Alaboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waddah","family":"Ashram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2024.102203_b0005","doi-asserted-by":"crossref","first-page":"e0278821","DOI":"10.1371\/journal.pone.0278821","article-title":"Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study","volume":"18","author":"Al Faraidy","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jsps.2024.102203_b0010","doi-asserted-by":"crossref","first-page":"e84350","DOI":"10.1371\/journal.pone.0084350","article-title":"Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment","volume":"9","author":"Al Sifri","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jsps.2024.102203_b0015","first-page":"A12904","article-title":"assessing low-density lipoprotein cholesterol risk in secondary prevention patients within the PINNACLE national outpatient registry","volume":"140","author":"Allen","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jsps.2024.102203_b0020","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/j.jacc.2020.03.072","article-title":"Small dense low density lipoprotein cholesterol predicts atherosclerotic cardiovascular disease in the Copenhagen General Population Study","volume":"75","author":"Balling","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jsps.2024.102203_b0025","first-page":"231","article-title":"First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study","volume":"32","author":"Barrios","year":"2020","journal-title":"Cl\u00ednica e Investig. En Arterioscler. (english Ed."},{"key":"10.1016\/j.jsps.2024.102203_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2022.02.008","article-title":"Trends in PCSK9 Inhibitor Utilization in the United States, Europe and Other Countries: An Analysis of International Sales Data","volume":"248","author":"Blais","year":"2022","journal-title":"Am. Heart J."},{"key":"10.1016\/j.jsps.2024.102203_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajmo.2023.100035","article-title":"PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration","volume":"9","author":"Eloso","year":"2023","journal-title":"Am. J. Med. Open"},{"key":"10.1016\/j.jsps.2024.102203_b0040","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.clinthera.2021.02.002","article-title":"Effectiveness, safety, and adherence to treatment of proprotein convertase subtilisin\/Kexin type 9 inhibitors in real practice","volume":"43","author":"Gayoso-Rey","year":"2021","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jsps.2024.102203_b0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jsps.2024.102203_b0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jsps.2024.102203_b0055","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jsps.2024.102203_b0060","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jsps.2024.102203_b0065","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cjco.2022.03.003","article-title":"Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study","volume":"4","author":"Gupta","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.jsps.2024.102203_b0070","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacl.2017.09.003","article-title":"Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Hovingh","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.jsps.2024.102203_b0075","doi-asserted-by":"crossref","first-page":"e006910","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.jsps.2024.102203_b0080","first-page":"S139","article-title":"Epidemiology and management of hyperlipidemia","volume":"23","author":"Karr","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.jsps.2024.102203_b0085","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jsps.2024.102203_b0090","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jsps.2024.102203_b0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jsps.2024.102203_b0100","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12325-021-01962-w","article-title":"Effectiveness, adherence, and safety of evolocumab in a swiss multicenter prospective observational study","volume":"39","author":"Nanchen","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jsps.2024.102203_b0105","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"Society Guidelines 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.jsps.2024.102203_b0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"S1","key":"10.1016\/j.jsps.2024.102203_b0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.jsps.2024.102203_b0120","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2024.102203_b0125","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9883352","article-title":"Current management guidelines on hyperlipidemia: the silent killer","volume":"2021","author":"Su","year":"2021","journal-title":"J. Lipids"},{"key":"10.1016\/j.jsps.2024.102203_b0130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.amjcard.2017.10.028","article-title":"Effect of evolocumab on lipoprotein particles","volume":"121","author":"Toth","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jsps.2024.102203_b0135","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamacardio.2019.5954","article-title":"Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease","volume":"5","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.jsps.2024.102203_b0140","article-title":"Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke","volume":"1\u201310","author":"Zhang","year":"2023","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016424002548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016424002548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:26:00Z","timestamp":1736184360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016424002548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1319016424002548"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2024.102203","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2024.102203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}],"article-number":"102203"}}